Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-HYDROCORT vs COMBIVENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.
Adrenocortical insufficiency (primary and secondary),Congenital adrenal hyperplasia,Inflammatory conditions (e.g., rheumatoid arthritis, ulcerative colitis),Allergic reactions (severe),Asthma exacerbations,Dermatologic disorders (topical use),Ophthalmic inflammation (ophthalmic use)
Treatment of chronic obstructive pulmonary disease (COPD) exacerbations,Acute asthma exacerbations (off-label)
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Ipratropium: terminal elimination half-life of approximately 2 hours (range 1.5-4 hours) after inhalation. Albuterol: terminal elimination half-life of approximately 3.8-6 hours after inhalation; systemic half-life is clinically relevant for dosing frequency in asthma/COPD.
Primarily hepatic via CYP3A4 and other CYP450 enzymes, with reduction in the A-ring to inactive metabolites (e.g., tetrahydrocortisol).
Ipramatropium: partially metabolized by hydrolysis to inactive metabolites; Albuterol: primarily metabolized by sulfate conjugation via SULT1A3 and to a lesser extent by CYP450 enzymes (CYP3A4, CYP2D6) to 4'-O-sulfate.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Ipratropium is primarily excreted renally as unchanged drug (approximately 50%) and metabolites (approximately 30%); fecal excretion accounts for about 10%. Albuterol undergoes hepatic metabolism to an inactive sulfate conjugate, with approximately 70-80% of a dose excreted renally as unchanged drug and metabolite; fecal excretion is minimal (<10%).
90-95% bound to corticosteroid-binding globulin (CBG) and albumin
Ipratropium: approximately 0-9% bound to plasma proteins (predominantly albumin). Albuterol: approximately 10% bound to plasma proteins.
0.5-0.8 L/kg; represents distribution into total body water, higher in obesity
Ipratropium: Vd approximately 2-4 L/kg (467 L for a 70 kg adult), indicating extensive tissue distribution. Albuterol: Vd approximately 1.5-2 L/kg (105-140 L for a 70 kg adult), consistent with moderate tissue distribution.
Oral: 96% (well absorbed); IM/IV: 100%; topical: minimal systemic absorption (<1% with intact skin)
Inhalation: Ipratropium absolute bioavailability of approximately 7-25% (due to pulmonary deposition and swallowed fraction). Albuterol inhaled bioavailability of approximately 10-20%. Oral bioavailability (swallowed) is low: ipratropium about 2-3%, albuterol about 30-50% but first-pass metabolism reduces systemic exposure.
No specific adjustment required; monitor fluid/electrolytes in severe renal impairment.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl >30 m L/min). Caution in severe impairment (Cr Cl <30 m L/min) or dialysis; use reduced frequency or alternative therapy due to potential for systemic accumulation.
Dose reduction may be necessary in severe hepatic impairment; caution as metabolism is hepatic.
No specific Child-Pugh based guidelines; caution in severe hepatic impairment (Child-Pugh class C) due to reduced clearance of albuterol, consider dose reduction or extended interval.
Doses are weight-based; for adrenal insufficiency: 0.5-0.75 mg/kg/day in divided doses; for anti-inflammatory: 0.5-10 mg/kg/day.
Not recommended for children <6 years. For ≥6 years: 2 inhalations 4 times daily as needed, up to 12 inhalations/day.
Use lowest effective dose; monitor for osteoporosis, hypertension, and glucose intolerance.
No specific dose adjustment; monitor for anticholinergic effects (e.g., dry mouth, urinary retention) and beta-adrenergic effects (e.g., tachycardia, tremor). Ensure proper inhaler technique; consider spacer use.
None.
None
Immunosuppression and increased infection risk,Adrenal suppression with prolonged use,Cushing's syndrome with chronic use,Osteoporosis with long-term use,GI perforation risk in inflammatory bowel disease,Growth suppression in children,Fetal harm (category C),Ocular effects (cataracts, glaucoma),Fluid and electrolyte disturbances
Paradoxical bronchospasm,Immediate hypersensitivity reactions,Deterioration in renal function (ipratropium eliminated renally),Cardiovascular effects: tachycardia, arrhythmias, hypertension (albuterol),Hypokalemia (albuterol),Increased intraocular pressure with nebulized ipratropium in glaucoma patients,Urinary retention in patients with prostatic hyperplasia or bladder neck obstruction
Systemic fungal infections,Hypersensitivity to hydrocortisone or any component,Administration of live or live-attenuated vaccines (relative),Herpes simplex keratitis (topical ophthalmic use),Peptic ulcer disease (relative),Uncontrolled hypertension (relative)
Hypersensitivity to ipratropium, albuterol, or any component of the formulation,Hypersensitivity to atropine or its derivatives
No specific food interactions. However, high-sodium foods may exacerbate fluid retention; a low-sodium diet is recommended if edema occurs. Grapefruit juice does not significantly affect hydrocortisone. Avoid alcohol due to additive gastric irritation.
No specific food interactions are clinically significant. Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase the risk of stimulant side effects (tremor, palpitations). Maintain adequate hydration to help manage possible dry mouth from ipratropium.
Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal adrenal suppression, growth restriction, and premature birth. Risk of premature rupture of membranes and intrauterine growth restriction increases with prolonged use.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium bromide showed no teratogenic effects. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: potential risk based on animal data. Second/third trimesters: albuterol may inhibit uterine contractions and cause maternal tachycardia, which may affect fetal heart rate; avoid near term due to possible neonatal hypoglycemia and hypokalemia.
Hydrocortisone is excreted into breast milk in low concentrations. M/P ratio approximately 0.4-1.0. Doses up to 20 mg/day are considered compatible with breastfeeding. Higher doses may suppress infant adrenal function; monitor infant for growth and adrenal suppression.
Unknown if albuterol or ipratropium are excreted in human milk. M/P ratio not established. Caution advised; consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on nursing infant.
Due to increased clearance and protein binding changes, doses may need to be increased by 50-100% in the second and third trimesters. Monitor clinical response and adjust dose accordingly. Stress doses (e.g., 50-100 mg IV) should be given during labor and delivery.
No specific dosing adjustment recommended for Combivent during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may affect albuterol; monitor clinical response and adjust dosing frequency if needed. Ipratropium has minimal systemic absorption; no adjustment anticipated.
For acute adrenal insufficiency, give IV bolus of 100 mg hydrocortisone followed by 100 mg every 8 hours. Taper to oral replacement over days. In septic shock, stress-dose hydrocortisone (200 mg/day) may be used if vasopressor-dependent. Monitor for hyperglycemia, hypokalemia, and immunosuppression. Abrupt discontinuation can cause adrenal crisis.
Combivent is a fixed-dose combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 agonist) for COPD exacerbations. It should be used with caution in patients with narrow-angle glaucoma, bladder neck obstruction, or prostatic hypertrophy. Shake well before use. Rinse mouth after inhalation to prevent oral candidiasis and dysphonia. Monitor for paradoxical bronchospasm, hypokalemia, and cardiovascular effects (tachycardia, hypertension). Not indicated for acute episodes of asthma or as rescue monotherapy; consider separate short-acting beta-agonist for acute symptoms.
Take exactly as prescribed; do not stop suddenly without doctor's guidance.,Carry a medical alert card or bracelet indicating you take hydrocortisone.,Report signs of adrenal crisis: severe weakness, dizziness, nausea, vomiting, abdominal pain.,During illness or stress (e.g., surgery, infection), dose may need temporary increase; contact your doctor.,Avoid live vaccines during therapy.,Monitor for weight gain, swelling, mood changes, or high blood sugar symptoms (increased thirst, urination).
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use (at least 10-15 seconds).,Prime the inhaler by spraying 4 test sprays into the air (away from face) before first use or if not used for more than 3 days.,Rinse your mouth with water after each use to reduce the risk of thrush (oral fungal infection) and hoarseness.,Seek immediate medical attention if you experience sudden worsening of breathing, chest pain, or signs of allergic reaction (rash, hives, swelling).,Inform your doctor if you have glaucoma, difficulty urinating, enlarged prostate, heart problems, or seizures.,Do not use with other inhaled medicines unless instructed by your doctor.,Keep inhaler clean; wipe mouthpiece with a dry cloth weekly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-HYDROCORT vs COMBIVENT, answered by our medical review team.
A-HYDROCORT is a Corticosteroid that works by Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.. COMBIVENT is a Bronchodilator Combination (Anticholinergic + Beta-2 Agonist) that works by Combivent is a fixed-dose combination of ipratropium bromide, an anticholinergic agent that inhibits muscarinic receptors in bronchial smooth muscle leading to bronchodilation, and albuterol sulfate, a beta-2 adrenergic agonist that stimulates adenyl cyclase, increasing cyclic AMP, resulting in bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-HYDROCORT and COMBIVENT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-HYDROCORT is: Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.. The standard adult dose of COMBIVENT is: 2 inhalations (ipratropium 18 mcg and albuterol 103 mcg per actuation) via oral inhalation 4 times daily; maximum 12 inhalations in 24 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-HYDROCORT and COMBIVENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-HYDROCORT is classified as Category C. Hydrocortisone is a corticosteroid. Use during first trimester is associated with increased risk of oral clefts (odds ratio 1.5-3.0). Second and third trimester use may cause fetal. COMBIVENT is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, albuterol sulfate showed teratogenicity (cleft palate) at high doses; ipratropium br. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.